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A Case Report Of Tragaxofusp Causing Severe 
Tumor Lysis Syndrome In A Patient With Blastic 
Plasmacytoid Dendritic Cell Neoplasm
Shuwen Lin, MD, Alice Wang, MD
INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is 
a rare and aggressive hematologic malignancy that 
does not respond to cytotoxic chemotherapies well. We 
present a case of BPDCN that was treated with a new 
targeted therapy tagraxofusp and the fatal complication 
that the patient developed with this treatment. 
HOSPITAL COURSE
The patient was an 83-year-old male without significant 
past medical history who presented to his primary care 
physician with several days of generalized malaise. He 
obtained routine bloodwork which showed a 
leukocytosis to 29 B/L. He then presented to the ED for 
further evaluation. Vitals were within normal limits and 
physical exam was remarkable for splenomegaly. Labs 
were significant for a WBC 44.7 B/L, Hgb 10 g/dL, 
platelets of 96 B/L, and the differential showed 20.6 B/L 
blasts. Creatinine was increased from a baseline of 1.20 
to 1.45mg/dL, potassium was 4.9mmol/L, phosphate 
was 3.1mg/dL, calcium was 8.5 mg/dL, lactate 
dehydrogenase was 2705 IU/L, and uric acid was 5.1mg/
dL.  A peripheral smear was done which showed 
immature leukocytes with blastic morphology. He was 
admitted for further hematologic malignancy workup.
Flow cytometry of the peripheral blood showed a 
population that was CD4+, CD7+(dim), CD33+(dim), 
CD38+(partial, bright), CD56+(partial, bright), CD 123+, 
HLA-DR+(bright) and a monoclonal CD5+CD23+ B cell 
population. These markers show an undifferentiated 
blast population specific for neither lymphoid nor 
myeloid lineage. Fluorescence in-situ hybridization (FISH) 
showed 17p (TP53) deletion, 13q deletion (D13S319 and 
LAMP1), and ZRSR2 mutations. A complete karyotype 
revealed multiple complex chromosomal abnormalities 
with the presence of two unrelated abnormal clones 
suggesting genomic instability as well as the clonal 
evolution of neoplastic cells. Bone marrow biopsy 
showed hypercellularity and 84% immature-appearing 
cells. The abnormal cells had following phenotype: 
CD4+, CD10,  CD13-, CD14-, CD16-, CD33+ (partial, dim), 
CD34-, CD38+, CD56+ (partial), CD64-, CD117- , 
HLA-DR+. These immature cells express CD123 and were 
negative for MPO by peripheral blood flow cytometry. 
By immunohistochemistry, the neoplastic cells were 
positive for CD4, CD43, CD56 (dim, partial), and TCL-1 
(diffuse and strong).  Notably, they were negative for 
CD68, CD163, lysozyme, and MPO. These findings are 
consistent with the diagnosis of blastic plasmacytoid 
dendritic cell neoplasm (BDPCN).  Additionally, flow 
cytometry detected a small monoclonal B-cell population 
(6%) with phenotype consistent with chronic lymphocytic 
leukemia/small lymphocytic lymphoma. Further 
assessment by computed tomography (CT) of the 
abdomen and pelvis revealed massive splenomegaly to 
23cm but did not show evidence of metastatic disease or 
lymphadenopathy in the chest, abdomen, and pelvis. 
The patient was subsequently started CD123 targeted 
therapy with tagraxofusp at a dose of  12 mcg/kg three 
days after admission. His lab values remained stable 
from admission to initiating therapy. On cycle 1. day 1, 
approximately 6 hours after he finished his first infusion, 
the patient was found to have altered mental status with 
increasing dyspnea and tachypnea to 50’s with 
desaturation to 80% on room air.  Labs obtained at the 
time showed a WBC 130.5 B/L, Hgb 9.5g/dL, platelets of 
102 B/L, and the differential showed 117.5 B/L blasts. His 
creatinine was 2.11mg/dL, potassium 7.4mmol/L, 
phosphate 10.9mg/L, LDH 20119 IU/L, and urate of 
5.8mg/dL. The patient was placed on non-invasive 
positive pressure ventilation and diuresis was given 
without significant improvement. The decision was 
made to intubate and he was transferred to the medical 
intensive care unit. The patient’s acute hypoxic respiratory 
failure was thought to be due to a combination of 
capillary leak syndrome and tumor lysis syndrome 
resulting in anuric acute kidney injury and fluid retention.
After his arrival to the intensive care unit, the patient was 
febrile with temperature 102.4 F, hypotensive with BP 
111/33, and bradycardic to 51 BPM. He was given more 
diuresis with IV furosemide 100mg and started on 
vancomycin and cefepime. Telemetry showed changes 
consistent with hyperkalemia including peaked T-waves 
and bradycardia. Temporizing measures were given 
including insulin, dextrose, and bicarbonate infusion. 
However, he ultimately required continuous veno-venous 
hemodialysis (CVVHD) due to the severity of his 
electrolyte derangements. During the patient’s ICU 
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course, he developed seizure-like activity. CT of the 
head was negative for any acute changes such as edema 
or hemorrhage. An electroencephalogram (EEG) was 
done but was negative for seizure activity. The patient 
then developed shock liver with elevations in AST 2859, 
ALT 2205, ALP 108, and had a lactate of 11.9. He also had 
multiple episodes of supraventricular tachycardia with 
heart rates up to 170 BPM, which required adenosine 
and cardiac resynchronization therapy. Due to the 
severity of the patient’s condition and the wishes of the 
patient’s family, aggressive care was stopped and the 
patient’s care was switched to comfort measures only. 
He passed away on cycle 1, day 4, after a palliative 
extubation.
DISCUSSION
BPDCN is an aggressive hematologic malignancy. One of 
the characteristics of this malignancy is that the neoplastic 
cells almost always overexpress interleukin-3 receptor 
subunit alpha (IL3RA or CD123). Tagraxofusp, as a 
CD123-directed cytotoxin consisting of recombinant 
human interleukin-3 fused to a truncated diphtheria toxin, 
targets this overexpression specifically.1 In 2019, a 
nonrandomized, multistage, open-label, multicenter 
evaluation of tagraxofusp as monotherapy in patients with 
BPDCN study was published in the NEJM and a 90% 
overall response rate was observed among patient with 
previously untreated BPDCN, and the majority of 
responses were complete remission. In contrast, prior to 
the development of tagraxofusp, there was no standard 
treatment for BPDCN. BPDCN was treated with cytotoxic 
chemotherapy regimens that were conventionally used 
for treating acute lymphoblastic leukemia/large B cell 
lymphoma, non-Hodgkin lymphoma, or acute myeloid 
leukemia but with very limited success. Although the 
standard-of-care remains untested in randomized fashion, 
tagraxofusp exhibits a higher rate of complete responses 
when used in the first-line setting. Because of this 
presumed efficacy and his advanced age putting him at 
higher risk for intensive induction chemotherapy, we 
chose tagraxofusp as our therapy of choice. 
The most serious adverse events of tagraxofusp that has 
been reported is capillary leak syndrome.2 Capillary leak 
syndrome is characterized by leakage of intravascular 
fluids into the extravascular space, leading to generalized 
edema, pulmonary edema and multiorgan failure. In the 
Pemmaraju et al study, 9 patients (19%) had capillary leak 
syndrome of various grade and two deaths that were 
attributed to capillary leak syndrome.  Tumor lysis 
syndrome was also described as a less common and less 
severe adverse event of tagraxofusp in this study. In total, 
11% of the patients had ≥ grade 3 tumor lysis syndrome.z 
However, no deaths were reported to be associated with 
tumor lysis syndrome.  
In our patient’s case, he developed an overwhelming 
response to the tragaxofusp immediately after his first 
dose. His anuric acute kidney injury secondary to tumor 
lysis syndrome led to metabolic derangements, cardiac 
instability and death. As potential adverse effects are not 
fully known for this new agent, we suggest that this case 
should raise awareness of the potential severity of tumor 
lysis syndrome with tagraxofusp. In addition, cytoreduction 
could be considered prior to the start of tagraxofusp in 
patients with high tumor burden to decrease the risks of 
developing tumor lysis syndrome. 
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